Notice of Annual Business Meeting
The 2024 PRS Annual Business Meeting will be held on Saturday, September 28 at 1:00 pm in the Cocoa Ballroom at the Hershey Lodge, Hershey PA.
Welcome to the Pennsylvania Rheumatology Society
The Pennsylvania Rheumatology Society (PRS) was established in 1987 to advance the knowledge of rheumatology and to foster the dissemination of this knowledge through educational endeavors and cooperation with other local and national societies of Rheumatology.
PRS has been working for more than thirty years to support the interests of rheumatologists and their patients in the state by keeping our members up to date on legislative issues impacting rheumatology, and encouraging timely member outreach on local, state and federal levels.
PRS provides significant funding support for training and education of Fellows. And for all, PRS provides CME opportunities, both in-person and virtual, relevant to the latest research in rheumatology.
​
Events
We're Back to the Sweetest Place on Earth!​
​
September 27--29, 2024
​
Annual Scientific Meeting
​
The Hershey Lodge
​
Hershey, PA
​
​
PRS Connect
On behalf of our collegue, ​Rohit Aggarwal:
Dear Pennsylvania Society of Rheumatology,
As a professor of medicine, in the Division of Rheumatology and Clinical Immunology at the University of Pittsburgh, I am writing to seek your invaluable support in disseminating crucial information regarding an innovative decentralized clinical trial focused on myositis-ILD to the esteemed rheumatology members of Florida Society of Rheumatology.
This pioneering clinical trial involves the use of Nintedanib in the treatment of Myositis-ILD (MINT study), providing patients with the opportunity to participate in the trial from the comfort of their own homes, regardless of their geographical location within the United States. Local rheumatologists and pulmonologists will serve as essential physician partners in this trial.
The burden imposed upon local rheumatologists and pulmonologists in this trial is minimal, limited solely to the referral of patients and the provision of necessary medical records. No additional regulatory obligations, such as IRB approval, are required.
For further information see clinicaltrial.gov: bit.ly/MINTstudy
Rohit Aggarwal MD MS
Medical Director, Arthritis and Autoimmunity Center
Professor of Medicine
Co-director, UPMC Myositis Center
Division of Rheumatology and Clinical Immunology
University of Pittsburgh
